<DOC>
	<DOCNO>NCT02956109</DOCNO>
	<brief_summary>Finerenone develop treatment diabetic kidney disease ( adult ) chronic kidney disease ( child ) . The purpose propose trial test pharmacokinetics single oral dose finerenone ( 1.25 mg tablet 5 x 0.25 mg tablet ) use novel orodispersible tablet formulation treatment child , comparison adult tablet formulation .</brief_summary>
	<brief_title>Study Finerenone Investigate Paediatric Formulation Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male subject Age : 18 45 year ( inclusive ) Body mass index ( BMI ) : ≥ 18 ≤ 29.9 kg/m² Race : White Subjects conspicuous finding medical history prestudy examination opinion investigator A history relevant diseases vital organ , central nervous system organ Known renal liver insufficiency Subjects diagnose malignancy , psychiatric disorder , thyroid disorder ( evaluated medical history , physical examination , clinical symptom , assessment thyroid stimulate hormone screening ) Medical disorder would impair subject 's ability complete study opinion investigator Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Relevant diseases within last 4 week prior first study drug administration Smoking 10 cigarette daily and/ inability refrain smoke profile day 8 h administration Vegetarian special diet prevent subject eat standard meal study , especially highfat highcalorie American breakfast reluctance ingest</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>